148 related articles for article (PubMed ID: 23563830)
1. Efficacy of voriconazole in experimental rat paracoccidioidomycosis.
Granzoto DS; Vitali LH; Martinez R
Rev Soc Bras Med Trop; 2013; 46(1):79-83. PubMed ID: 23563830
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of fluconazole and amphotericin B in the parenteral treatment of experimental paracoccidioidomycosis in the rat.
Martinez R; Malta MH; Verceze AV; Arantes MR
Mycopathologia; 1999; 146(3):131-4. PubMed ID: 10823185
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activity of the new azole UK-109, 496 (voriconazole).
Kappe R
Mycoses; 1999; 42 Suppl 2():83-6. PubMed ID: 10865910
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
5. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.
Queiroz-Telles F; Goldani LZ; Schlamm HT; Goodrich JM; Espinel-Ingroff A; Shikanai-Yasuda MA
Clin Infect Dis; 2007 Dec; 45(11):1462-9. PubMed ID: 17990229
[TBL] [Abstract][Full Text] [Related]
6. Paracoccidioidomycosis.
Marques SA
Clin Dermatol; 2012; 30(6):610-5. PubMed ID: 23068148
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of antifungal drugs against Paracoccidioides brasiliensis and Paracoccidioides lutzii in a Galleria mellonella model.
de Lacorte Singulani J; Scorzoni L; de Paula E Silva AC; Fusco-Almeida AM; Mendes-Giannini MJ
Int J Antimicrob Agents; 2016 Sep; 48(3):292-7. PubMed ID: 27444116
[TBL] [Abstract][Full Text] [Related]
8. Modest efficacy of voriconazole against murine infections by Sporothrix schenckii and lack of efficacy against Sporothrix brasiliensis.
Fernández-Silva F; Capilla J; Mayayo E; Guarro J
Mycoses; 2014 Feb; 57(2):121-4. PubMed ID: 23879298
[TBL] [Abstract][Full Text] [Related]
9. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of the efficiency of itraconazole and ketoconazole in the treatment of experimental paracoccidioidomycosis].
Negroni R; Finquelievich JL; Gosis AS
Med Cutan Ibero Lat Am; 1987; 15(6):455-60. PubMed ID: 2828779
[TBL] [Abstract][Full Text] [Related]
11. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
12. Chronic murine paracoccidioidomycosis: effect of ketoconazole on clearance of Paracoccidioides brasiliensis and immune response.
Hoyos GL; McEwen JG; Brummer E; Castañeda E; Restrepo A; Stevens DA
Sabouraudia; 1984; 22(5):419-26. PubMed ID: 6095472
[TBL] [Abstract][Full Text] [Related]
13. Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis.
Laties AM; Fraunfelder FT; Tomaszewski K; Goodrich J; Moreira AT; Sato MT; de Queiroz-Telles F
Clin Ther; 2010 Dec; 32(13):2207-17. PubMed ID: 21316537
[TBL] [Abstract][Full Text] [Related]
14. A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole.
Lignell A; Johansson A; Löwdin E; Cars O; Sjölin J
Clin Microbiol Infect; 2007 Jun; 13(6):613-9. PubMed ID: 17378925
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods].
Sancak B; Alp S; Hasçelik G; Arikan S
Mikrobiyol Bul; 2009 Apr; 43(2):269-76. PubMed ID: 19621612
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis.
Travassos LR; Silva LS; Rodrigues EG; Conti S; Salati A; Magliani W; Polonelli L
J Antimicrob Chemother; 2004 Nov; 54(5):956-8. PubMed ID: 15448128
[TBL] [Abstract][Full Text] [Related]
18. Treatment of paracoccidioidomycosis with itraconazole in a murine model.
McEwen JG; Peters GR; Blaschke TF; Brummer E; Perlman AM; Restrepo A; Stevens DA
J Trop Med Hyg; 1985 Oct; 88(5):295-9. PubMed ID: 3014164
[TBL] [Abstract][Full Text] [Related]
19. [In vitro sensitivity of Paracoccidioides brasiliensis to systemically used antifungal agents].
Rodero L; Canteros CE; Rivas C; Lee W; Davel G
Rev Argent Microbiol; 1999; 31(2):78-81. PubMed ID: 10425663
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activities of azole agents against the Malassezia species.
Miranda KC; de Araujo CR; Costa CR; Passos XS; de Fátima Lisboa Fernandes O; do Rosário Rodrigues Silva M
Int J Antimicrob Agents; 2007 Mar; 29(3):281-4. PubMed ID: 17223320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
